Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median

被引：6
|
作者：
Chiumente, Marco [1 ]
Mengato, Daniele [2 ]
Messori, Andrea [3 ]
机构：
[1] Italian Soc Clin Pharm & Therapeut, Sci Direct, Milan, Italy
[2] Bolzano Cent Hosp, Dept Hosp Pharm, Bolzano, Italy
[3] Reg Hlth Serv, HTA Unit, Florence, Italy
来源：
ACTA HAEMATOLOGICA | 2020年 / 143卷 / 06期
关键词：
D O I：
10.1159/000505891
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：598 / 599
页数：2
相关论文
共 50 条
  • [1] Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
    Messori, Andrea
    Chiumente, Marco
    Mengato, Daniele
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [2] RELATIONSHIP BETWEEN RESPONSE RATES AND PROGRESSION-FREE SURVIVAL IN NON-HODGKIN'S LYMPHOMA
    Mangal, N.
    Salem, A. H.
    Li, M.
    Menon, R.
    Freise, K. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S38 - S39
  • [3] Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival
    McClune, Brian L.
    Ahn, Kwang Woo
    Wang, Hai-Lin
    Antin, Joseph H.
    Artz, Andrew S.
    Cahn, Jean-Yves
    Deol, Abhinav
    Freytes, Cesar O.
    Hamadani, Mehdi
    Holmberg, Leona A.
    Jagasia, Madan H.
    Jakubowski, Ann A.
    Kharfan-Dabaja, Mohamed A.
    Lazarus, Hillard M.
    Miller, Alan M.
    Olsson, Richard
    Pedersen, Tanya L.
    Pidala, Joseph
    Pulsipher, Michael A.
    Rowe, Jacob M.
    Saber, Wael
    van Besien, Koen W.
    Waller, Edmund K.
    Aljurf, Mahmoud D.
    Akpek, Goergun
    Bacher, Ulrike
    Chao, Nelson J.
    Chen, Yi-Bin
    Cooper, Brenda W.
    Dehn, Jason
    de Lima, Marcos J.
    Hsu, Jack W.
    Lewis, Ian D.
    Marks, David I.
    McGuirk, Joseph
    Cairo, Mitchell S.
    Schouten, Harry C.
    Szer, Jeffrey
    Ramanathan, Muthalagu
    Savani, Bipin N.
    Seftel, Matthew
    Socie, Gerard
    Vij, Ravi
    Warlick, Erica D.
    Weisdorf, Daniel J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (07) : 960 - 968
  • [4] Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients
    Li, Mengyao
    Dave, Nimita
    Salem, Ahmed Hamed
    Freise, Kevin J.
    MEDICINE, 2017, 96 (35)
  • [5] Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence
    Morschhauser, Franck
    Dreyling, Martin
    Rohatiner, Ama
    Hagemeister, Fredrick
    Delaloye, Angelika Bischof
    ONCOLOGIST, 2009, 14 : 17 - 29
  • [6] Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials
    Mangal, Naveen
    Salem, Ahmed Hamed
    Li, Mengyao
    Menon, Rajeev
    Freise, Kevin J.
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 37 - 43
  • [7] Autologous stem cell transplants result in better 5-year overall, but not progression-free, survival than allogeneic transplants in patients with indolent non-Hodgkin's lymphoma.
    Lin, TS
    Elder, PJ
    Penza, SL
    Avalos, BR
    Farag, SS
    Molina, A
    Mrozek, E
    Belt, PS
    Porcu, P
    Marcucci, G
    Byrd, JC
    Copelan, EA
    BLOOD, 2002, 100 (11) : 644A - 645A
  • [8] Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation
    Bachanova, Veronika
    Weisdorf, Daniel J.
    Wang, Tao
    Marsh, Steven G. E.
    Trachtenberg, Elizabeth
    Haagenson, Michael D.
    Spellman, Stephen R.
    Ladner, Martha
    Guethlein, Lisbeth A.
    Parham, Peter
    Miller, Jeffrey S.
    Cooley, Sarah A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (09) : 1602 - 1607
  • [9] Interim FDG PET/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL)
    Knight-Greenfield, Ashley
    Marshall, Richard Aaron
    Hutchings, Martin
    Doucette, John
    Stern, Jamie
    Coleman, Morton
    Kostakoglu, Lale
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma
    Khashab, Tamer
    Hagemeister, Fredrick
    Romaguera, Jorge E.
    Fanale, Michelle A.
    Pro, Barbara
    McLaughlin, Peter
    Rodriguez, M. Alma
    Neelapu, Sattva S.
    Fayad, Luis
    Younes, Anas
    Feng, Lei
    Vega, Francisco
    Kwak, Larry W.
    Samaniego, Felipe
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (04) : 670 - 678
12345